Arcanobacterium (Actinomyces) pyogenes, an animal pathogen, produces a hemolytic exotoxin, pyolysin (PLO). The gene encoding PLO was cloned, and sequence analysis revealed an open reading frame of 1,605 bp encoding a protein of 57.9 kDa. PLO has 30 to 40% identity with the thiol-activated cytolysins (TACYs) of a number of gram-positive bacteria. The activity of PLO was found to be very similar to those of other TACYs, except that it was not thiol activated. The highly conserved TACY undecapeptide is divergent in PLO; in particular, the cysteine residue required for thiol activation has been replaced with alanine. However, mutagenesis of the alanine residue to cysteine did not confer thiol activation on PLO, suggesting a conformational difference in the undecapeptide region of this toxin. Specific antibodies against purified, recombinant PLO completely neutralized the hemolytic activity of A. pyogenes, suggesting that this organism produces a single hemolysin. Furthermore, these antibodies could passively protect mice against lethal challenge with A. pyogenes, suggesting that like other TACYs PLO is an important virulence factor in the pathogenesis of this organism.
scribed previously (3) , were sequenced by the dideoxy chain termination method (38) with Sequenase (U.S. Biochemicals). Sequencing was performed on both strands, crossing all restriction sites. DNA sequence data were confirmed by automated sequencing on a 373A DNA sequencer (Applied Biosystems, Inc.).
Cloning and purification of recombinant His-PLO. The plo gene, lacking the coding region for the predicted signal sequence, was amplified from A. pyogenes BBR1 genomic DNA by PCR with a 5Ј primer containing an XhoI site (5Ј-ACAGCATCCTCGAGTGCCGGATTGGGAAAC-3Ј) and a 3Ј primer containing an EcoRI site (5Ј-TGGAATTCCCTAGGATTTGACATTGT-3Ј). This 1.5-kb PCR fragment was digested with XhoI-EcoRI and cloned into XhoIEcoRI-digested pTrcHis B (Invitrogen) to generate pJGS59. The entire insert of pJGS59 was sequenced to confirm that no mutations were introduced by PCR. Cultures for the preparation of His-tagged PLO (His-PLO) or His-PLO.C 492 were grown to an optical density at 600 nm of 0.6 prior to induction with 5 mM isopropyl-␤-D-thiogalactopyranoside (IPTG; Gold Biotechnology) for 3 h. Cells were harvested by centrifugation at 5,000 ϫ g, and the cell pellet was resuspended in phosphate-buffered saline (PBS; 0.01 M; pH 7.2). The cells were disrupted by two passages through a French pressure cell (Aminco) at 138 MPa, and the insoluble material was removed by centrifugation at 12,000 ϫ g. His-PLO was purified from the soluble fraction with TALON metal affinity resin (Clontech) according to the manufacturer's instructions. Protein concentration was determined with BCA protein assay reagent (Pierce).
Site-directed mutagenesis. Site-directed mutagenesis of pJGS59 was performed with the Transformer site-directed mutagenesis kit (Clontech) according to the manufacturer's directions. The selection primer (5Ј-GACTTGGTT GAGGCCTCACCAGTCAC-3Ј) was designed to change the ScaI site of pTrcHis B to StuI, while the mutagenic primer (5Ј-GAAGCAGGCGA GTGCACTGGCCTAGC-3Ј) was designed to change codon 492 of plo from GCA (Ala) to TGC (Cys). Introduction of this mutation into plasmid pJGS89 was confirmed by DNA sequencing.
Preparation of goat antiserum to His-PLO (␣-His-PLO).
An adult female goat was immunized with 500 g of His-PLO in Ribi Adjuvant System (Ribi ImmunoChem Research Inc.) administered intramuscularly in the hind leg at two sites. A similar booster immunization of 600 g of His-PLO in Ribi Adjuvant System was administered 25 days later. Blood was collected on day 46, and antiserum was harvested from the clotted blood. Preimmune serum was collected in a similar manner prior to immunization.
Passive immunization of mice with ␣-His-PLO. Groups of six female, 6-to 8-week-old ICR mice (Harlan Sprague Dawley) were immunized intraperitoneally with 0.5 ml of PBS, preimmune serum, or ␣-His-PLO on day Ϫ1 and day 0. The mice were challenged intraperitoneally with 2.3 ϫ 10 8 CFU of log-phase A. pyogenes BBR1 8.5 h after the last immunization (day 0). Mice were euthanized on days 4, 7, and 13 postchallenge or when moribund. Peritoneal fluid (PF) was obtained by lavage with 3 ml of PBS. Blood and liver were aseptically removed, and the liver was macerated by passage through a 3-cm 3 syringe. Serial dilutions of PF, blood, and liver were inoculated onto BHI-blood agar to determine bacterial viable counts. Smears of PF were stained with DiffQuik (Dade Diagnostics).
Hemolytic assays. Micotitration hemolytic assays were performed essentially as described by Bhakdi et al. (6) , except that a final concentration of 0.25% washed ovine blood cells was used. One hemolytic unit (HU) was defined as the amount of hemolysin releasing 50% of the hemoglobin from 200 l of 0.25% sheep erythrocytes in 1 h. The hemolytic titer was the reciprocal of the highest dilution which resulted in 50% sheep erythrocyte lysis. The effect of reducing and thiol-blocking compounds on hemolytic activity was assayed by incubation of 1,280-HU/ml hemolysin preparations with either 2.5 mM dithiothreitol (DTT), 2% ␤-mercaptoethanol (␤-ME), or 500 M 5,5Ј-dithiobis(2-nitro-benzoic acid) (DTNB) (all concentrations are final) for 10 min or with 1 mM (final concentration) N-ethylmaleimide (MalNEt) for 30 min at room temperature prior to hemolytic assay. To assay for cholesterol inhibition, 100-l volumes of cholesterol in absolute ethanol were added to 1-ml aliquots of 1,280-HU/ml hemolysin preparations, to final concentrations of 1 g/ml or 100 ng/ml. After a 30-min incubation at room temperature, the hemolytic assay was performed as described above, with hemolysin preparations incubated with 100 l of absolute ethanol as controls.
The antihemolytic titers of sera were assessed by incubating 5 HU of PLO with serial twofold dilutions of serum at 37°C for 30 min prior to assaying for hemolytic activity as described above. The antihemolytic titer was the reciprocal of the antibody dilution which completely neutralized hemolytic activity.
SDS-PAGE and Western blotting. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting were performed essentially as described by Ausubel et al. (3) . Immunostaining of Western blots was performed as previously described (11) , with rabbit anti-goat immunoglobulin G (heavy plus light chains)-peroxidase conjugate (Kirkegaard & Perry Laboratories, Inc.) as the secondary antibody.
Computer analysis. Nucleotide sequence data were compiled by using the Sequencher program (GeneCodes, Ann Arbor, Mich.). Database searches were performed by using the BlastX and BlastP algorithms (2) . Sequence analysis was performed with the suite of programs available through the Genetics Computer Group, Inc. (University of Wisconsin). Phylogenetic analysis was performed with PHYLIP, the phylogenetic analysis package (University of Washington).
Nucleotide sequence accession number. The nucleotide sequence data reported in this paper have been deposited in the DDBJ, EMBL, and GenBank nucleotide sequence databases under accession number U84782.
RESULTS
Cloning and expression of the A. pyogenes plo gene. The plo gene encoding the hemolysin, PLO, of A. pyogenes BBR1 was cloned in E. coli with selection for hemolytic activity on blood agar as described in Materials and Methods. Two hemolytic colonies were obtained, and the resulting cosmids, ApH1 and ApH2, overlapped significantly in a restriction endonuclease profile. Successive subcloning from ApH1 yielded plasmid pAp350, which contained a 3.5-kb EcoRI-XhoI fragment (Fig.  1) . pAp350 was still able to confer hemolytic activity on E. coli DH5␣, but all attempts to reduce the size of pAp350 resulted in nonhemolytic recombinants. An identically sized 3.5-kb EcoRI-XhoI fragment was detected in BBR1 genomic DNA by Southern blotting with a digoxigenin-labeled probe derived from the insert of pAp350 (data not shown).
Nucleotide sequence of the A. pyogenes plo gene. Nucleotide sequence data obtained from pAp350 revealed an open reading frame (ORF) of 1,605 bp (Fig. 2) . Deletions extending into this ORF yielded nonhemolytic colonies, suggesting that this ORF encoded an A. pyogenes hemolysin. The gene containing the ORF was designated plo. The plo gene was preceded by a consensus ribosome binding site and a region of DNA with similarity to the E. coli 70 consensus promoter sequences (Fig.  2) . Upstream of the putative promoter sequence are a pair of 11-bp perfect direct repeats. In addition, the plo gene was followed by a region of dyad symmetry which may act as a transcriptional terminator but which lacked the string of T residues generally associated with these structures (Fig. 2) . Searches of the protein databases indicated that the translated PLO product had 31.2 to 40.6% identity and 48.0 to 55.8% similarity with the TACY family of pore-forming toxins produced by Bacillus alvei, Clostridium perfringens, L. monocytogenes, Streptococcus pneumoniae, Streptococcus pyogenes, and other gram-positive bacteria (16, 17, 23, 29, 33, 46, 47) .
Twenty isolates of A. pyogenes were subjected to PCR analysis using primers designed to amplify a 455-bp fragment internal to the plo gene. All isolates produced identical bands of the appropriate size (data not shown), suggesting that the gene encoding PLO is present in most, if not all, A. pyogenes isolates.
Analysis of the primary structure of PLO. The predicted PLO protein is 534 amino acids (aa) in length, with a deduced molecular mass of 57.9 kDa. This presumably represents a 
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on November 7, 2017 by guest http://jb.asm.org/ precursor form of the protein, as there is a consensus signal peptidase cleavage site between aa 27 and 28 of the protein (Fig. 2) . The predicted mature form of PLO would be 55.1-kDa with an isoelectric point (pI) of 9.3. These values are in good agreement with molecular mass and pI values obtained for purified native PLO (13) . The TACY family is characterized by a highly conserved undecapeptide located near the C terminus of the protein. While much of this sequence is also conserved in PLO, there is some divergence within the PLO undecapeptide (Fig. 3A) . The Cys residues within the undecapeptides of TACYs are responsible for the oxygen-labile nature of these hemolysins (30, 35, 39) . However, PLO possesses an Ala at this position, and there are no Cys residues in the molecule. In addition, the insertion of a Pro residue within a region of clustered Trp residues (Fig. 3A) , implicated in cholesterol and membrane binding of TACYs (32, 41) , may have significant effects on the binding of PLO to eukaryotic membranes. To confirm the divergent nature of the PLO undecapeptide, the nucleotide sequences across the undecapeptide-coding regions of plo genes from A. pyogenes OX1, OX8, and ATCC 19411 were obtained from PCR products, and in each case the sequence was identical to the sequence from strain BBR1.
Alignment of the nine TACYs for which complete amino acid sequences are available with the amino acid sequence of PLO indicated that 92 residues were totally conserved. Tyr (10 of 18 residues), Pro (8 of 24 residues), and Trp (6 of 8 residues) were conserved at high frequencies with respect to their frequencies within the PLO molecule (Fig. 2) . Three of the six conserved Trp residues are in the undecapeptide sequence (Fig. 3A) , while two are contained within a domain implicated in the antibody-independent activation of complement by pneumolysin (PLY) (31) . The amino acids demonstrated to be involved in this activity are also conserved in PLO (Fig. 3B) .
Phylogenetic comparisons of members of the TACY family indicated that while PLO is clearly a member of this family, it is the most divergent member (Fig. 4) . Its closest relatives within the family are the cytolysins of Listeria spp., but in general terms it showed a similar level of identity (30 to 40%) with all members of the family.
Construction and expression of a His-plo gene fusion. To facilitate the purification of recombinant PLO from E. coli, the PLO-coding sequence, lacking the coding sequence for the putative signal peptide, was cloned into pTrcHis B. This construct, pJGS59 (Fig. 1) , encoded a 543-aa protein composed of 507 aa of the mature PLO with an N-terminal extension of 36 aa encoded by pTrcHis B, including a six-HIS sequence. SDS-PAGE analysis of IPTG-induced cultures of DH5␣FЈlacI q (pJGS59) indicated the presence of an overexpressed protein of approximately 59 kDa which was not present in induced cultures of DH5␣FЈlacI q (pTrcHis B) (Fig. 5A ). The size of this protein corresponded to that predicted for the N-terminal His-tagged PLO molecule (His-PLO). DH5␣FЈlacI q (pJGS59) was hemolytic on LB agar supplemented with 5% bovine blood, indicating that His-PLO retained hemolytic activity. His-PLO was purified to near homogeneity (Fig. 5A ) and retained hemolytic activity in purified form. completely neutralized 5 HU of activity from both A. pyogenes BBR1 CSF and His-PLO to a titer of 1,024. Complete inhibition of hemolytic activity by ␣-His-PLO suggested that PLO was the only hemolysin produced by strain BBR1. Preimmune serum also neutralized BBR1 hemolytic activity but only to a titer of 4, possibly due to a low level of anti-PLO antibodies resulting from natural exposure to A. pyogenes. In Western blots, ␣-His-PLO recognized both the His-PLO protein expressed from pJGS59 (data not shown) and recombinant PLO expressed from its own promoter in pAp350 (Fig. 5B) . In several rounds of Western blotting, ␣-His-PLO failed to recognize a protein of the appropriate molecular weight in concentrated BBR1 CSF. However, when 20-times-concentrated BBR1 CSF was extensively dialyzed prior to use as an antigen in Western blotting experiments, ␣-His-PLO reacted with a number of protein bands (Fig. 5B ) which were not recognized by preimmune serum (data not shown). A major reactive band at approximately 52 kDa probably represented the monomeric form of PLO. A number of higher-molecular-weight reactive bands, including antigen retained in the stacking gel, may represent aggregated PLO molecules and may have contributed to the inability to detect native PLO in earlier experiments. The lower-molecular-weight reactive bands may represent degradation products of PLO, as concentrated supernatants from stationary-phase cultures have significant levels of protease activity (data not shown).
PLO activity is insensitive to reducing agents. Funk et al. (14) reported that the activity of A. pyogenes hemolysin was unaffected by reducing compounds. To confirm this observation, crude PLO and crude and purified His-PLO were preincubated with either ␤-ME or DTT prior to being assayed for hemolytic activity. In each case there was no effect of reducing agents on hemolytic titer compared to a control preparation of LLO, which exhibited at least a 16-fold increase in hemolytic titer in the presence of reducing agents (Table 1) .
To confirm whether the lack of the conserved Cys in the undecapeptide was responsible for the oxygen-insensitive, or non-thiol-activated, nature of PLO, site-directed mutagenesis was performed on pJGS59 to change the Ala residue (A 492 ) at position 2 of the undecapeptide to Cys. The resulting plasmid was designated pJGS89. In crude extracts, the modified His-PLO molecule (His-PLO.C 492 ), like its parent, showed no increase in hemolytic titer in the presence of reducing agents (Table 1) . To confirm that modification of the free thiol group of His-PLO.C 492 did not affect hemolytic activity, assays were repeated with purified His-PLO.C 492 in the presence of DTNB or MalNEt. The activity of His-PLO.C 492 was inhibited 25% by either DTNB or MalNEt compared with a Ͼ98% inhibition of recombinant C. perfringens perfringolysin O (PFO) ( Table 1) . The thiol-reactive compounds had no effect on the activity of His-PLO. Purified His-PLO.C 492 (88 HU/g) had a specific activity comparable to that of His-PLO (128 HU/g), indicating that this mutation had only a marginal effect on activity.
PLO activity is sensitive to cholesterol. Differences between PLO and other members of the TACY family in the undecapeptide region led us to speculate that PLO may interact differently with cholesterol in the cell membrane. The ability of free cholesterol to inhibit the hemolytic activity of PLO or His-PLO was compared with its ability to inhibit thiol-activated LLO. The activity of each hemolysin was inhibited 75% by incubation with 1 g of free cholesterol per ml, but no inhibition was observed in the presence of 100 ng of free cholesterol per ml (Table 1 ). This result is in contrast to that of a previous study in which the activity of A. pyogenes hemolysin was reported to be insensitive to cholesterol at a concentration of 1 g/ml (14) .
Passive protection of mice with ␣-His-PLO. The lethality of PLO to mice precluded active immunization with this toxin (27) , and passive immunization was undertaken as an alterna- (pJGS59 and pJGS89, respectively) . c LLO preparations were stored at 4°C for Ͼ2 weeks and had lost all detectable activity in the absence of reducing agents. d Hemolytic assay performed in the presence of 2% ␤-ME.
tive approach. ␣-His-PLO, but not preimmune serum or PBS, passively protected mice against A. pyogenes BBR1 infection. Mice receiving ␣-His-PLO showed no sign of illness, nor could any viable bacteria be recovered from blood, PF, or liver. In contrast, all mice receiving only PBS were dead or moribund by day 5, with average bacterial counts of 9.1 ϫ 10 3 CFU/ml in blood, 8.8 ϫ 10
8 CFU/ml in PF, and 1.9 ϫ 10 10 CFU/g in liver (Table 2) . DiffQuik-stained smears of PF indicated that A. pyogenes BBR1 was readily phagocytosed by peritoneal macrophages and PMN. However, a significant proportion of the bacteria were associated with lysed phagocytes (data not shown), suggesting that A. pyogenes may kill, rather than be killed by, these cells. Five of six mice which received preimmune serum showed signs of illness, with average bacterial counts of 1.4 ϫ 10 3 CFU/ml in blood, 6.6 ϫ 10 8 CFU/ml in PF, and 7.0 ϫ 10 8 CFU/g in liver ( Table 2) . Three of these mice were moribund by day 11. It should be noted that the preimmune serum had an antihemolytic titer of 4, compared with 1,024 for ␣-His-PLO. Low levels of antibodies to PLO are difficult to avoid due to the prevalence of A. pyogenes in adult animals (26) . These low levels of antibodies may have given rise to the increased survival times observed for mice immunized with preimmune serum compared with those for the PBS-immunized group. However, there were significant differences in signs of illness and bacterial viable counts between these two control groups and the group immunized with ␣-His-PLO.
DISCUSSION
We have demonstrated that the A. pyogenes hemolytic exotoxin, PLO, is a member of the TACY family of pore-forming toxins and is probably the sole hemolysin produced by this organism. Despite its clear relationship with the TACYs, PLO is clearly the most divergent member of the family. In addition, PLO is deficient in two of the defining characteristics of this group of proteins. First, its hemolytic activity is not thiol activated, a characteristic for which the group is named. However, because it has been demonstrated that some TACYs do not exhibit this function in purified form (1, 21, 39) , perhaps thiol activation does not clearly define this group of toxins. Second, while PLO has sequence similarity to the conserved TACY undecapeptide, it possesses significant changes in what is virtually an invariant sequence in all other TACYs. It is the first member of this family to be identified with Ala instead of Cys at position 2 of the undecapeptide, although Cys-to-Ala mutations at this position in PLY, streptolysin O (SLO), and LLO result in oxygen-stable molecules (30, 35, 39) . It is possible that thiol activation of TACYs regulates cytolytic activity in vivo, although, at least in the case of LLO, the Cys-to-Ala mutation results in LLO which exhibits no significant difference in virulence from wild-type LLO in a mouse model (30) .
It seemed logical to speculate that the lack of the conserved Cys in the undecapeptide of PLO was the sole reason that PLO did not exhibit thiol activation. However, clearly this is not the case, as His-PLO.C 492 is not activated in the presence of reducing agents. The PLO undecapeptide has other changes with respect to the conserved sequence. Insertion of a Pro residue and deletion of the terminal conserved Arg residue are likely to have significant effects on both the conformation and charge of the undecapeptide region. Indeed, insertion of the Pro residue is likely to disrupt the potentially amphiphilic helical structure of this region. The oxygen-labile nature of the TACYs is likely due to the reactive thiol group of the Cys residue interacting with reactive groups on other proteins (35) , thus blocking participation of the undecapeptide region in the cytolytic functions of the molecule. It is possible that conformational changes in the variant PLO undecapeptide may prevent occlusion of the undecapeptide by reactive proteins associated with the Cys residue of His-PLO.C 492 . This hypothesis is supported by the fact that modification of the free thiol group of His-PLO.C 492 with thiol blocking reagents results in a small inhibitory effect but not the major effect seen with other TACYs (21) .
Trp residues within the undecapeptide of PFO are intrinsically involved in the interaction of this TACY with target cell membranes (41) and may interact directly with cholesterol (32) . The changes in the PLO undecapeptide, particularly the insertion of the Pro which alters the spacing between Trp residues, are likely to change the conformation of the Trp residues with respect to each other. The cholesterol inhibition studies suggest that both native and recombinant PLOs and LLO are inhibited by free cholesterol in a similar manner. Of course, this does not necessarily indicate that the interactions of PLO and other TACYs with the target membrane are similar.
Among the conserved residues over the entire amino acid (Fig. 3B) (8, 31) , although only SLO has been demonstrated to bind complement (7). The conserved Pro residues are of considerable interest because of the propensity of this residue to form bends in protein molecules (9) . Pro residues are often located at the limits of functional domains and are intimately involved in protein folding and tertiary structure (9) . In addition to the eight totally conserved Pro residues, another five are conserved in at least 8 of the 10 TACY protein sequences. We propose that the conserved Pro residues are important in the conformation of TACYs, either in determining their monomeric forms or in exposing sites for oligomerization within target membranes. Only the C-terminal Pro has been mutagenized in PLY, but this resulted in a significant decrease in the ability of PLY to bind to erythrocyte membranes (34) . Many TACYs are involved in the pathogenic mechanisms of their producers. Knockout mutations in genes encoding PLY and LLO result in significant attenuation of the virulence of S. pneumoniae (5) and L. monocytogenes (15) in mouse models. LLO has been particularly well studied and is required for the escape of L. monocytogenes from the macrophage phagosome, allowing intracellular proliferation (12) . A significant reduction in necrosis was observed with a C. perfringens pfo mutant in a mouse myonecrosis model, although the major toxin involved in this disease is clearly alpha-toxin (4) . Similarly, the ability of antibodies against PLO to passively protect mice suggests important roles for this toxin, both as a virulence factor and also as a host-protective antigen. PLO may mediate macrophage or PMN lysis and, hence, escape from the phagocytic process, contributing to the virulence of A. pyogenes. This hypothesis is supported by studies of purified native PLO in which it displayed time-and dose-dependent cytotoxic effects on bovine PMN (13) .
The precise role of PLO in the pathogenesis of A. pyogenes is still unknown. Construction of, and mouse challenge with, an isogenic plo mutant will allow more precise determination of the role of PLO in virulence. These experiments will be facilitated by the recent development of an electroporation protocol for A. pyogenes (22) . Vaccination of mice and other target animals, such as cattle, with toxoided recombinant PLO preparations, followed by challenge, will allow determination of the efficacy of immunization with PLO for host protection. These experiments are currently being undertaken in this laboratory.
